Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1021-1040 of 2,120 trials

Rhabdomyosarcoma: New Treatment Combinations

We are studying new chemotherapy and radiotherapy options for children and adults with Rhabdomyosarcoma. The goal is to see if these new treatments improve outcomes compared to standard therapies.

RhabdomyosarcomaSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncologyPediatrics

Systemic Lupus Erythematosus: Obexelimab Study

We are studying a new medication, Obexelimab, for patients with systemic lupus erythematosus to see if it can lower disease activity and reduce fatigue. This trial compares its effects to a placebo treatment.

Systemic Lupus Erythematosus6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInternal MedicineRheumatology

Intranasal COVID-19 Vaccine: LVT-001

We are studying a new intranasal booster vaccine for COVID-19 to see if it is safe and more effective than the standard mRNA vaccine. This trial is for healthy adults who want to help improve COVID-19 vaccination strategies.

COVID-191-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInfectious Diseases

Kidney Transplant Rejection: INTERCEPT Study

We are studying whether adding TCZ to standard treatment helps kidney transplant recipients with chronic rejection maintain better kidney function. The trial also looks at the safety of this treatment and its effects on overall health.

Chronic Active Antibody-Mediated Rejection>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineNephrology

Glioma Treatment Study: Temozolomide and Lomustine

We are testing a combination of chemotherapy and radiotherapy for patients with newly diagnosed grade 2 or 3 glioma. The goal is to see if this approach improves survival compared to standard treatments.

Newly Diagnosed Glioma>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOncology

Parkinson's Disease: New Approaches to Levodopa Resistance

We are studying whether the medication apomorphine or the antibiotic rifaximin can help people with Parkinson's disease who struggle with levodopa treatment. This trial aims to improve their symptoms and overall treatment response.

Parkinson's Disease6-12 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementInternal MedicineNeurology

Acute Heart Failure: Diuretic Treatment Study

We are investigating the best diuretic strategies for patients with acute heart failure and volume overload. This study aims to improve treatment options for those at risk of diuretic resistance.

Acute Heart Failure>2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteCardiologyInternal Medicine

Denosumab: Impact on Muscle Strength and Insulin Sensitivity

We are studying whether denosumab can improve muscle strength and insulin sensitivity in participants. This trial compares its effects to a placebo to understand its potential benefits.

Diabetes MellitusPostmenopausal Osteoporosis6-12 monthsMonitoring phase (IV)Standard MedicinesEndocrinologyHepatologyInternal Medicine

Acute Myeloid Leukemia: Venetoclax and Azacitidine Treatment

We are studying whether a combination of venetoclax and azacitidine can help clear residual disease in AML patients before a stem cell transplant. This trial also looks at the safety and effectiveness of this treatment approach.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Soft Tissue Sarcoma: Oral Cyclophosphamide vs Doxorubicin

We are comparing the effectiveness of oral cyclophosphamide and doxorubicin in treating elderly patients with advanced soft tissue sarcoma. The goal is to find out which treatment may lead to better outcomes and fewer side effects.

Soft Tissue SarcomaConfirmation phase (III)No PlaceboStandard MedicinesOncology

Advanced Solid Tumors: BT5528 Treatment Study

We are testing a new drug, BT5528, for patients with advanced solid tumors that express EphA2. The study aims to evaluate its safety and effectiveness, both alone and with another medication.

Malignant Solid Tumor1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Chronic Migraine: Eptinezumab for Teens

We are studying whether eptinezumab can help reduce the number of migraine days in adolescents aged 12 to 17 with chronic migraine. This trial compares the medication to a placebo to assess its effectiveness.

Migraine3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Zanamivir for Infants with Complicated Influenza

We are studying how safe and effective intravenous zanamivir is for hospitalized infants under 6 months with complicated influenza. This research aims to understand how the drug works in young children.

Human Influenza>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious DiseasesPediatrics

HIV Prevention: Long-Acting Injectable Cabotegravir vs. Daily Oral Medication

We are studying whether a long-acting injectable form of cabotegravir is more effective than daily oral medication for preventing HIV in men who have sex with men. This trial aims to understand how well each option works over time and their impact on participants' health and behaviors.

HIV Prevention>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesInternal Medicine

Follicular Lymphoma: Tazemetostat with Lenalidomide and Rituximab

We are studying the safety and effectiveness of tazemetostat combined with lenalidomide and rituximab in adults with relapsed or refractory follicular lymphoma. This trial compares the new treatment to a placebo to see how well it works.

Relapsed/Refractory Follicular Lymphoma>2 yearsConfirmation phase (III)>20 visitsInvestigational MedicinesHematologyOncology

Mpox Booster Vaccine: Fractional vs. Full Dose

We are studying whether a smaller booster dose of the MVA-BN vaccine is as effective as the standard dose in adults. This trial will also look at the safety and immune response of both doses.

Mpox (Monkeypox)3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious Diseases

External Cephalic Version: Propofol vs. Spinal Analgesia

We are comparing the use of Propofol and spinal analgesia for sedation during a procedure to turn breech babies. Our goal is to find out which method has a higher success rate and fewer complications.

External Cephalic Version>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsInternal Medicine

Soft Tissue Sarcoma: MEK and PDL1 Inhibitor Combination

We are studying a new treatment combining two medications for patients with advanced soft tissue sarcoma. This trial aims to confirm safety and evaluate how well the treatment works in both children and adults.

Advanced or Metastatic CancerSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Soft Tissue Sarcomas: Atezolizumab with Radiotherapy

We are studying whether adding an immunotherapy drug to radiotherapy helps patients with localized soft tissue sarcomas achieve better treatment outcomes. The trial will also look at the safety and immune response to this combination.

Localized Soft Tissue Sarcoma3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncology

VEXAS Syndrome: Azacitidine Treatment Study

We are studying whether Azacitidine can help reduce symptoms and improve health in patients with VEXAS Syndrome. The trial will also assess the safety of this treatment and its impact on patients' quality of life.

VEXAS Syndrome>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyRheumatology